{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:20:12Z","timestamp":1775640012826,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.seminhematol.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:25:49Z","timestamp":1725704749000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Accelerating accessibility of CAR-T\/NK therapies \u2013 Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-824X","authenticated-orcid":false,"given":"Sridevi","family":"Rajeeve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Hoskote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.001_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1053\/j.seminhematol.2024.09.001_bib0002","first-page":"314","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet (British edition)"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0003","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206475","article-title":"Editorial: T-cell directed therapies in multiple myeloma","volume":"13","author":"Richter","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.001_bib0005","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0007","unstructured":"Society IM. After ODAC Review: FDA Approves abecma and carvykti in earlier lines of therapy for relapsed or refractory myeloma patients. https:\/\/www.myeloma.org\/blog\/dr-duries\/fda-approves-abecma-and-carvykti-in-earlier-treatment-of-RRMM. Accessed: 10\/2\/24."},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0009","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2021-153204","article-title":"Phase i first-in-class trial of MCARH109, a g protein coupled receptor class c group 5 member d (GPRC5D) targeted car t cell therapy in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0012","article-title":"BMS-986393 (CC-95266), a g protein\u2013coupled receptor class c group 5 member d (GPRC5D)\u2013targeted chimeric antigen receptor (car) t-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"7","author":"Susan Bal","year":"2023","journal-title":"2023 American Society of Hematology Annual Meeting"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0013","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Therapy - Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.001_sbref0016","article-title":"How do you decide?\u2019: Cancer treatment's CAR-T crisis has patients dying on a waitlist","author":"Chen","year":"2022","journal-title":"STAT"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40487-023-00228-5","article-title":"Component costs of car-t therapy in addition to treatment acquisition costs in patients with multiple myeloma","volume":"11","author":"Jagannath","year":"2023","journal-title":"Oncol Therapy"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0018","article-title":"Senescent T cells: a potential biomarker and target for cancer therapy","volume":"68","author":"Zhang","year":"2021","journal-title":"EBio Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"118.e1","DOI":"10.1016\/j.jtct.2021.11.016","article-title":"Absolute lymphocyte count prior to lymphodepletion impacts outcomes in multiple myeloma patients treated with chimeric antigen receptor t cells","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/cancers15030567","article-title":"Non-conventional allogeneic anti-bcma chimeric antigen receptor-based immune cell therapies for multiple myeloma treatment","volume":"15","author":"Du","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0023","article-title":"Umbilical cord blood: a promising source for allogeneic CAR-T cells","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of car-t cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2008.03.008","article-title":"T cell receptor specificity for major histocompatibility complex proteins","volume":"20","author":"Marrack","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2021-147738","article-title":"Immunicy-1: targeting BCMA with Cyad-211 to establish proof of concept of an shRNA-based allogeneic car t cell therapy platform","volume":"138","author":"Al-Homsi","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0029","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2021-145572","article-title":"Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 Therapy for relapsed\/refractory multiple myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140641","article-title":"Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the Anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma","volume":"136","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141477","article-title":"Preclinical evaluation of ALLO-605, an allogeneic BCMA turbocar TTM cell therapy for the treatment of multiple myeloma","volume":"136","author":"Sommer","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0032","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nature Medicine"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0033","doi-asserted-by":"crossref","first-page":"TPS8063","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8063","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma (CAMMOUFLAGE trial)","volume":"41","author":"Berdeja","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0034","unstructured":"AG CT. A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma. NCT04244656. CLinicalTrialsgov. 2023; https:\/\/clinicaltrials.gov\/study\/NCT04244656. Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_sbref0035","article-title":"Poseida therapeutics I. P-BCMA-ALLO1 allogeneic CAR-T cells in the treatment of subjects with multiple myeloma (MM)","year":"2021","journal-title":"ClinicalTrialsgov"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0036","unstructured":"Precision BioSciences I. A dose-escalation study to evaluate the safety and clinical activity of PBCAR269A, with or without nirogacestat, in study participants with relapsed\/refractory multiple myeloma. ClinicalTrialsgov. 2019; https:\/\/clinicaltrials.gov\/study\/NCT04171843?term=PBCAR269A&rank=1; https:\/\/clinicaltrials.gov\/study\/NCT04171843?term=A%20dose-escalation%20study%20to%20evaluate%20the%20safety%20and%20clinical%20activity%20of%20PBCAR269A,%20with%20or%20without%20nirogacestat&rank=1 Accessed: 10\/2\/24."},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0037","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0038","unstructured":"SA CO. Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1). ClinicalTrialsgov. 2020; https:\/\/clinicaltrials.gov\/study\/NCT04613557?term=IMMUNICY-1&rank=1 Accessed: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_sbref0039","series-title":"mSMART Startification for Myeloma and Risk Adapted Therapy","author":"Clinic","year":"2022"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Seminars in Oncology"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.001_bib0041","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0042","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.001_bib0043","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0044","unstructured":"Therapeutics F. FT576 in Subjects With Multiple Myeloma NCT05182073. ClinicalTrialsgov. 2024; https:\/\/clinicaltrials.gov\/study\/NCT05182073?term=NCT05182073&rank=1 Accessed: 10\/2\/24."},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267475","article-title":"V\u03b39V\u03b42 T cells expressing a BCMA\u2014Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth","volume":"17","author":"Zhang","year":"2022","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0046","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T Therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.001_bib0047","doi-asserted-by":"crossref","first-page":"334","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.001_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030404","article-title":"Chimeric antigen receptor beyond caR-T Cells","volume":"13","author":"Qin","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.001_bib0049","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer t cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.001_bib0050","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-Cell (CAR-T), in patients with relapsed \/refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0051","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2018-99-116443","article-title":"Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma","volume":"132","author":"Dar","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0052","unstructured":"S.A. C. Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed\/Refractory Multiple Myeloma (MELANI-01). ClinicalTrialsgov. 2019; https:\/\/clinicaltrials.gov\/study\/NCT04142619. Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0053","unstructured":"Shenzhen Pregene Biopharma Co. L. Clinical Study of the Safety and Efficacy of BCMA CAR-NK (NCT05652530). ClinicalTrialsgov. 2022; https:\/\/clinicaltrials.gov\/study\/NCT05652530?term=NCT05652530&rank=1 Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0054","unstructured":"Hrain Biotechnology Co. L. To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R\/R MM or PCL. 2023; https:\/\/clinicaltrials.gov\/study\/NCT06045091?term=%20NCT06045091%20&rank=1 Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0055","unstructured":"Sciences SBUoM. Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma. CLinicalTrialsgov. 2024; https:\/\/clinicaltrials.gov\/study\/NCT06242249?term=Anti-BCMA%20CAR-NK%20Therapy%20in%20Relapsed%20or%20Refractory%20Multiple%20Myeloma.&rank=1 Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0056","unstructured":"Asclepius Technology Company Group (Suzhou) Co. L. Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse\/Refractory MM. CLinicalTrialsgov. 2019; https:\/\/clinicaltrials.gov\/study\/NCT03940833?term=Clinical%20Research%20of%20Adoptive%20BCMA%20CAR-NK%20Cells%20on%20Relapse%2FRefractory%20MM&rank=1 Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0057","unstructured":"Chongqing XHo. Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma. CLinicalTrialsgov. 2021; https:\/\/clinicaltrials.gov\/study\/NCT05008536?term=Anti-BCMA%20CAR-NK%20Cell%20Therapy%20for%20the%20Relapsed%20or%20Refractory%20Multiple%20Myeloma&rank=1 Accessed date: 10\/2\/24."},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.001_bib0059","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive t-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2023-189196","article-title":"ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501\/501A in Patients (Pts) with Relapsed\/Refractory (r\/r) Large B-Cell and Follicular Lymphomas","volume":"142","author":"Locke","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0061","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","article-title":"P370: early results of a safety and efficacy study of allogeneic truucar\u2122 gc502 in patients with relapsed\/refractory b-cell acute lymphoblastic leukemia (r\/r b-all)","volume":"6","author":"Li","year":"2022","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0062","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 Axis and virus infections: a delicate balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"5455","key":"10.1053\/j.seminhematol.2024.09.001_bib0063","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.287.5455.1031","article-title":"Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40","volume":"287","author":"Tomasec","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0064","doi-asserted-by":"crossref","unstructured":"Younes S, Zhao S, Bharadwaj S, et al. Detection of aberrant cd58 expression in a wide spectrum of lymphoma subtypes: implications for treatment resistance. mod pathol. Oct 2023;36(10):100256. doi:10.1016\/j.modpat.2023.100256","DOI":"10.1016\/j.modpat.2023.100256"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0065","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","article-title":"Engineering immune-evasive allogeneic cellular immunotherapies","volume":"24","author":"Martin","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.001_bib0066","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jtct.2024.01.058","article-title":"CARving a path forward: unveiling t cell phenotypes across the spectrum of multiple myeloma disease progression to inform future strategies for overcoming resistance to car t therapy","volume":"30","author":"Ferreri","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7897","key":"10.1053\/j.seminhematol.2024.09.001_bib0067","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.001_bib0068","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0069","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Therapy - Methods & Clinical Development"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.001_bib0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/bioengineering9120808","article-title":"Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies","volume":"9","author":"Ganeeva","year":"2022","journal-title":"Bioengineering"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.001_bib0071","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Comm"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0072","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood-2021-146268","article-title":"A first-in-human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T cell therapy manufactured using the novel t-charge tm platform, for the treatment of patients (Pts) with relapsed\/refractory (r\/r) diffuse large b-cell lymphoma (DLBCL)","volume":"138","author":"Flinn","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.001_bib0073","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discovery"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0074","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the first phase 1 clinical study of the b-cell maturation antigen (BCMA) nex t chimeric antigen receptor (car) t cell therapy cc-98633\/bms-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.001_bib0076","unstructured":"Ltd. GB. A Study of GC012F in patients with relapsed\/refractory multiple myeloma NCT06235229. ClinicalTrialsgov. 2024;"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.09.001_bib0077","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400091X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400091X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:37:17Z","timestamp":1729010237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632400091X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S003719632400091X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating accessibility of CAR-T\/NK therapies \u2013 Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}